If Sumitomo was willing to pay $2 for CYP years ago, I wouldn't want to accept anything less than $4+, considering all the progress made and the demonstrated clinical efficacy. Not to mention that Cynata holds the only global patents for converting IPSCs to MSCs.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.0¢ | $29.18K | 176.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 66467 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 65000 | 1 |
View Market Depth
| Last trade - 15.59pm 25/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |